All News
Filter News
Found 539,907 articles
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results
2/21/2019
Rigel Pharmaceuticals, Inc. announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28, 2019.
-
Intrexon to Announce Fourth Quarter 2018 Financial Results on February 28th
2/21/2019
Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, announced it will release fourth quarter 2018 financial results after the market closes on Thursday, February 28th, 2019.
-
MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation
2/21/2019
MPM Capital, a life-sciences venture capital firm investing in early-stage therapeutics companies, announced the closing of its seventh venture fund, BioVentures 2018.
-
Nucleix's Non-Invasive Bladder EpiCheck™ Biomarker Test Allows for Personalized Monitoring of Bladder Cancer
2/21/2019
Prof. Shahrokh F. Shariat: "Using Bladder EpiCheck as a rule-out test, can reduce 80% of cystoscopies without missing a single high-grade cancer" Finding recently published in BJU international
-
CHA Health Systems Subsidiary to Form the Largest Healthcare Network to Provide Premium Comprehensive Suite of Medical Services
2/21/2019
CHS increased the share of SMG to approximately 24% to form the largest healthcare network in the Asia-Pacific region to develop a world-class oncology program, wellness center, and women’s health center
-
Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2/21/2019
Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced that the Company will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST in New York, NY.
-
Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD
2/21/2019
Landos Biopharma, Inc. announced the publication of findings that further elucidate the regulatory arm of the novel mechanism of action for BT-11, its investigational new drug for Crohn’s disease and ulcerative colitis, in the Journal of Immunology.
-
Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2/21/2019
Ra Pharmaceuticals, Inc. announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the Lotte New York Palace, New York, NY.
-
Firmly on our way to becoming a fully integrated biopharma company
2/21/2019
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
-
The Medicines Company Announces Upcoming Investor Conference Presentations
2/21/2019
The Medicines Company announced today that management will present company overviews at the following conferences
-
Insilico and Teva enter collaboration to apply predictive Digital Twins for biopharmaceutical production
2/21/2019
Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.
-
Exicure to Present at the 12th Annual European Life Sciences CEO Forum
2/21/2019
Exicure, Inc. announced that its CEO, Dr. David Giljohann, will present a corporate update at the 12th Annual European Life Sciences CEO Forum being held February 25-26, 2019 at the Hilton Zurich Airport Hotel in Zurich, Switzerland.
-
Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance
2/21/2019
Denovo Biopharma announced the hiring of two senior executives, reporting to the CEO: Lei Zhang, MD, as Chief Medical Officer, Hematology, and Bruce M. Wagman, as Senior Vice President, Regulatory Affairs and Quality Assurance.
-
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
2/21/2019
AbbVie announced that they have received approval for an additional indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa.
-
Diagnostic Solutions Laboratory Revolutionizes Precision Medicine with GenomicInsight™ Genomic Health Profile Powered by Opus23 Explorer™
2/21/2019
Diagnostic Solutions Laboratory continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight™ Genomic Health Profile powered by Opus23 Explorer™
-
Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
2/21/2019
DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients
-
Terramera secures USD $10 million in financing from BDC
2/21/2019
Investment will help Vancouver-based cleantech firm commercialize technologies that promise to revolutionize agriculture
-
Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
2/21/2019
Correvio Pharma Corp. announced that Correvio's management team will participate in 1-on-1 meetings at the 8th Annual SVB Leerink Healthcare Conference at the Lotte New York Palace on Thursday, February 28, 2019 in New York City.
-
MorphoSys to Present at Upcoming Investor Conference
2/21/2019
MorphoSys AG will present at the following conference.
-
Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
2/21/2019
Audentes Therapeutics, Inc., will host a conference call and webcast to report its fourth quarter and full year 2018 financial results and provide a corporate update on Wednesday, February 27, 2019.